Skip to main content

Table 2 Demographic and clinical characteristic of people living with HIV/AIDS diagnosed with TB at enrollment and during follow-up in the ClinSurv HIV Cohort, Germany 2001–2011

From: Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors

Characteristics   Female Male Total
   N = 66 (28.3%) N = 167 (71.7%) N = 233 (100%)
Median age at enrollment (N = 232/1 missing data) Median [IQR] 31 [26–45] 40 [32–47] 37 [30–45]
Median age at the time of TB diagnosis, years (N = 251/1 missing data) Median [IQR] 32 [28–39] 40 [32–48] 37 [31–45]
Region of origin (N = 223/10 missing data) N. (%)    
   Germany   8 (12.5) 81 (50.9) 89 (39.9)
   Sub-Saharan Africa   41 (64.1) 41 (25.8) 82 (36.8)
   Other countries   15 (23.4) 37 (23.3) 52 (23.3)
HIV-transmission risk group (N = 214/19 missing data) N. (%)    
   MSM   --- 67 (43.8) 67 (31.3)
   PWID   3 (4.9) 17 (11.1) 20 (9.4)
   HPC   54 (88.5) 43 (28.1) 97 (45.3)
   Others   4 (6.6) 26 (16.9) 30 (14.0)
Median CD4+ blood cell count at enrollment (N = 221/12 missing data) Median [IQR] 197 [67–349] 204 [67–375] 189 [66–348]
Median CD4+ blood cell count at the time of TB diagnosis (N = 194/39 missing data) Median [IQR] 211 [65–339] 198 [47–339] 216 [69–350]
Median viral load at enrollment (log10copies/ml) (N = 210/23 missing data) Median [IQR] 4.8 [3.6-5.4] 4.7 [3.4-5.5] 4.9 [3.6-5.3]
Median viral load at the time of TB diagnosis (N = 145/88 missing data) Median [IQR] 5.0 [4.3-5.6] 5.2 [4.5-5.7] 5.9 [3.9-5.5]
Hepatitis B* (N = 233) Median [IQR] 25 (37.9) 39 (23.4) 64 (27.5)
Hepatitis C* (N = 233) Median [IQR] 5 (7.6) 18 (10.8) 23 (9.9)
Diabetes mellitus* (N = 233) Median [IQR] 2 (3.0) 5 (3.0) 7 (3.0)
cART (N = 233) Median [IQR] 31 (50.0) 99 (59.3) 130 (55.8)
Died (N = 233) N. (%) 4 (10.6) 18 (10.8) 25 (10.7)
  1. TB, tuberculosis; MSM, men who have sex with men; PWID, person who inject drugs; HPC, high HIV-prevalence countries; cART, combination antiretroviral therapy; IQR, interquartile range.
  2. *At any time during follow-up.
  3. Others included heterosexual, blood transfusion and mother to child transmission.
  4. cART initiated during follow-up at any time prior to TB diagnosis.